Pardes Biosciences, Inc. (PRDS)
Price:
2.18 USD
( + 0.02 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
NEWS
Pardes Biosciences Announces Closing of Tender Offer
globenewswire.com
2023-08-31 08:15:00CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
businesswire.com
2023-08-28 11:33:00LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the “CVR”) associ.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-19 06:30:00LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-18 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
businesswire.com
2023-08-17 17:43:00LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not mor.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-09 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-08 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
businesswire.com
2023-08-07 16:16:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc. Under the terms of the proposed transaction, MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amou.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-06 10:28:00LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-05 07:00:00LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-04 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-03 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-01 04:00:00LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-31 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
accesswire.com
2023-07-29 07:00:00LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-25 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
No data to display
Pardes Biosciences Announces Closing of Tender Offer
globenewswire.com
2023-08-31 08:15:00CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
businesswire.com
2023-08-28 11:33:00LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the “CVR”) associ.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-19 06:30:00LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-18 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
businesswire.com
2023-08-17 17:43:00LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not mor.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-09 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-08 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
businesswire.com
2023-08-07 16:16:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc. Under the terms of the proposed transaction, MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amou.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-06 10:28:00LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-05 07:00:00LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-04 05:00:00LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-03 06:00:00LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-08-01 04:00:00LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-31 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
accesswire.com
2023-07-29 07:00:00LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com
2023-07-25 06:00:00LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.